1.
Škof E. Experience with olaparib in the treatment of recurrent ovarian epithelial cancer with mutations in the BRCA 1 and BRCA 2 genes. Onkologija [Internet]. 2021 May 20 [cited 2021 Nov. 28];25(1):12-6. Available from: https://revijaonkologija.si/Onkologija/article/view/464